Actively Recruiting
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Led by Sixth Affiliated Hospital, Sun Yat-sen University · Updated on 2026-01-26
198
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study focuses on patients with H. pylori-positive resectable locally advanced adenocarcinoma of the gastric and oesophagogastric junction. It evaluates the perioperative oxaliplatin with S-1 (SOX) combined H. pylori eradication versus oxaliplatin with S-1 in the management of H. pylori-positive locally advanced adenocarcinoma of the gastric and oesophagogastric junction (cT3/4a Nx or T2 N2/3, M0) , assessing their values and advantages.
CONDITIONS
Official Title
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fully informed and voluntarily signed informed consent
- Diagnosed with locally advanced adenocarcinoma of the stomach or gastroesophageal junction confirmed by gastroscopy pathology
- Clinical staging at diagnosis of cT3/4a Nx or T2 N2/3, M0
- Confirmed current Helicobacter pylori infection by rapid urease test, tissue staining, bacterial culture, urea breath test, stool antigen test, or serum antibody test (if untreated)
- Age between 18 and 75 years, any sex
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- Organ function suitable for major abdominal surgery
- Expected survival of at least 6 months
- Laboratory test results within 7 days before enrollment meet specified blood counts, liver and kidney function, and coagulation parameters
- Ability to complete required endoscopic, laboratory, and imaging tests
- Agree to use contraception and avoid breastfeeding as specified if of childbearing potential
You will not qualify if you...
- Stage IV or unresectable gastric or gastroesophageal junction cancer
- Other active cancers within the last 5 years or currently
- History of organ or bone marrow transplantation or preparing for it
- Recent myocardial infarction or poorly controlled arrhythmia within 6 months
- Severe heart failure (NYHA class III-IV) or left ventricular ejection fraction below 50%
- Active or recent pulmonary tuberculosis
- Known active or suspected autoimmune disease requiring systemic immunosuppression
- Received live vaccine within 28 days before first dose, except seasonal influenza vaccine
- Use of systemic corticosteroids or immunosuppressive drugs above specified doses within 14 days before first dose or during study (with exceptions)
- Participation in another clinical study with treatment ending less than 14 days before this study
- History of severe allergies to study drug ingredients
- History of psychotropic drug abuse or drug addiction
- Other severe or acute medical conditions judged unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Sixth Affiliated Hospital，Sun Yat-sen University
Guangzhou, China
Actively Recruiting
Research Team
B
Bin Zhong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here